Home » Stocks » PRAH

PRA Health Sciences, Inc. (PRAH)

Stock Price: $142.81 USD -1.52 (-1.05%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $147.55 +4.74 (3.32%) Mar 2, 5:21 PM
Market Cap 9.36B
Revenue (ttm) 3.18B
Net Income (ttm) 197.04M
Shares Out 63.35M
EPS (ttm) 3.04
PE Ratio 46.98
Forward PE 26.04
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $142.81
Previous Close $144.33
Change ($) -1.52
Change (%) -1.05%
Day's Open 144.88
Day's Range 142.70 - 145.95
Day's Volume 2,013,475
52-Week Range 58.67 - 155.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

PRNewsWire - 4 days ago

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities...

GlobeNewsWire - 4 days ago

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims ...

Other stocks mentioned: RTP, SFTW
PRNewsWire - 6 days ago

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PRA Health Sciences Inc. ("PR...

PRNewsWire - 6 days ago

MILWAUKEE, Feb. 24, 2021 /PRNewswire/ -- Ademi LLP is investigating PRA Health (NASDAQ: PRAH) for possible breaches of fiduciary duty and other violations of law in its transaction with Icon. ...

Benzinga - 6 days ago

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS),...

Other stocks mentioned: PSTX, SLRX, SNSS
The Motley Fool - 6 days ago

The company released its fourth-quarter earnings report, but that doesn't tell the whole story.

GlobeNewsWire - 6 days ago

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PR...

Other stocks mentioned: ICLR
Business Wire - 6 days ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PRA Health Sciences, Inc. (NASDAQ: PRAH) to ICON plc is fair to PRA Health ...

Benzinga - 6 days ago

Shares of PRA Health Sciences (NASDAQ:PRAH) rose 20.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 0.65% year over year to $1.55, whi...

Zacks Investment Research - 6 days ago

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 5.44% and 5.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

Benzinga - 6 days ago

ICON plc (NASDAQ: ICLR) has agreed to acquire PRA Health Sciences Inc (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion. The per-share consideration consists o...

GlobeNewsWire - 6 days ago

RALEIGH, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us," or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended ...

Business Wire - 6 days ago

DUBLIN--(BUSINESS WIRE)--ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research

Other stocks mentioned: ICLR
GlobeNewsWire - 3 weeks ago

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, Februa...

Newsfile Corp - 1 month ago

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction TreatmentToronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awa...

GlobeNewsWire - 2 months ago

PRA's remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality PRA's remote p...

Zacks Investment Research - 2 months ago

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.

Other stocks mentioned: DXCM, TDOC
GlobeNewsWire - 3 months ago

Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA's industry-leading DCT practice Dr. Isaac Rodriguez-Chavez brings vast expert...

Seeking Alpha - 3 months ago

PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Zacks Investment Research - 3 months ago

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 15.04% and 3.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 3 months ago

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September ...

Zacks Investment Research - 4 months ago

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

RALEIGH, N.C., Oct. 07, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2020 results after the market closes on Wednesday, November 4, 2020. Th...

GlobeNewsWire - 4 months ago

With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health

Seeking Alpha - 5 months ago

PRA Health Sciences: A Solid Investment Case But Watch Out For Signs Of Inertia

Zacks Investment Research - 5 months ago

PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.

Zacks Investment Research - 5 months ago

Asian countries have already shown clear signs of major economic recession.

Other stocks mentioned: DGX, LH, MDRX, TMO, VEEV, ZM
GlobeNewsWire - 5 months ago

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials The two companies...

GlobeNewsWire - 5 months ago

RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effe...

Zacks Investment Research - 5 months ago

PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.

Zacks Investment Research - 5 months ago

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 5 months ago

RYE BROOK, N.Y. and RALEIGH, N.C.

Zacks Investment Research - 6 months ago

PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.

Seeking Alpha - 6 months ago

PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of PRA Health Sciences (NASDAQ:PRAH) rose 1.24% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

RALEIGH, N.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” “we,” “us” or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended June 30,...

Zacks Investment Research - 7 months ago

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 7 months ago

A Relative Strength Rating upgrade for PRA Health Sciences shows improving technical performance. Will it continue?

GlobeNewsWire - 8 months ago

U.S. law requiring clinical research for pediatric oncology treatments goes into effect mid-August 2020 U.S. law requiring clinical research for pediatric oncology treatments goes into effect ...

Zacks Investment Research - 8 months ago

PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.

GlobeNewsWire - 8 months ago

RALEIGH, N.C., June 12, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with th...

Zacks Investment Research - 9 months ago

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

Seeking Alpha - 10 months ago

PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.96% and 3.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

PRA Health Sciences (PRAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 10 months ago

PRA Health (PRAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

About PRAH

PRA Health Sciences, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assuran... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 13, 2014
CEO
Colin Shannon
Employees
18,100
Stock Exchange
NASDAQ
Ticker Symbol
PRAH
Full Company Profile

Financial Performance

In 2020, PRAH's revenue was $3.18 billion, an increase of 3.82% compared to the previous year's $3.07 billion. Earnings were $197.04 million, a decrease of -18.92%.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for PRAH stock is "Buy." The 12-month stock price forecast is 144.70, which is an increase of 1.32% from the latest price.

Price Target
$144.70
(1.32% upside)
Analyst Consensus: Buy